Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TransCon RBZ - Ascendis Pharma

Next Previous
Drug Profile

TransCon RBZ - Ascendis Pharma

Alternative Names: EYC-0305; TransCon-RBZ

Latest Information Update: 23 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascendis Pharma
  • Class Eye disorder therapies; Immunoglobulin fragments; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Wet age-related macular degeneration

Most Recent Events

  • 12 Feb 2026 Ascendis Pharma plans clinical trials for Wet age-related macular degeneration in 2026
  • 29 Jan 2024 Ascendis Pharma enters into a licensing agreement with Eyconis to develop, manufacture, and commercialize TransCon ophthalmology assets globally
  • 01 May 2023 Preclinical trials in Wet age-related macular degeneration in Denmark (unspecified route) (Ascendis Pharma Pipeline, May 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top